These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 31883913)

  • 1. PD-L1 status in breast cancer: Current view and perspectives.
    Vranic S; Cyprian FS; Gatalica Z; Palazzo J
    Semin Cancer Biol; 2021 Jul; 72():146-154. PubMed ID: 31883913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The recent advances of PD-1 and PD-L1 checkpoint signaling inhibition for breast cancer immunotherapy.
    Setordzi P; Chang X; Liu Z; Wu Y; Zuo D
    Eur J Pharmacol; 2021 Mar; 895():173867. PubMed ID: 33460617
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epithelial Expressed B7-H4 Drives Differential Immunotherapy Response in Murine and Human Breast Cancer.
    Wescott EC; Sun X; Gonzalez-Ericsson P; Hanna A; Taylor BC; Sanchez V; Bronzini J; Opalenik SR; Sanders ME; Wulfkuhle J; Gallagher RI; Gomez H; Isaacs C; Bharti V; Wilson JT; Ballinger TJ; Santa-Maria CA; Shah PD; Dees EC; Lehmann BD; Abramson VG; Hirst GL; Brown Swigart L; van ˈt Veer LJ; Esserman LJ; Petricoin EF; Pietenpol JA; Balko JM
    Cancer Res Commun; 2024 Apr; 4(4):1120-1134. PubMed ID: 38687247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Development of PD-1/PD-L1 Inhibitors in Breast Cancer: Still a Long Way to Go.
    Barroso-Sousa R; Tolaney SM
    Curr Treat Options Oncol; 2020 Jun; 21(7):59. PubMed ID: 32556894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted delivery of anti-miRNA21 sensitizes PD-L1
    Kim EH; Choi J; Jang H; Kim Y; Lee JW; Ryu Y; Choi J; Choi Y; Chi SG; Kwon IC; Yang Y; Kim SH
    Theranostics; 2024; 14(10):3777-3792. PubMed ID: 38994018
    [No Abstract]   [Full Text] [Related]  

  • 6. PD-1/PD-L1 counterattack alliance: multiple strategies for treating triple-negative breast cancer.
    Zhu H; Du C; Yuan M; Fu P; He Q; Yang B; Cao J
    Drug Discov Today; 2020 Sep; 25(9):1762-1771. PubMed ID: 32663441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation.
    Segovia-Mendoza M; Romero-Garcia S; Lemini C; Prado-Garcia H
    J Immunol Res; 2021; 2021():6668573. PubMed ID: 33506060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1.
    Bertucci F; Gonçalves A
    Curr Oncol Rep; 2017 Aug; 19(10):64. PubMed ID: 28799073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor Mutational Burden and
    Barroso-Sousa R; Keenan TE; Pernas S; Exman P; Jain E; Garrido-Castro AC; Hughes M; Bychkovsky B; Umeton R; Files JL; Lindeman NI; MacConaill LE; Hodi FS; Krop IE; Dillon D; Winer EP; Wagle N; Lin NU; Mittendorf EA; Van Allen EM; Tolaney SM
    Clin Cancer Res; 2020 Jun; 26(11):2565-2572. PubMed ID: 32019858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer.
    Noguchi E; Shien T; Iwata H
    Jpn J Clin Oncol; 2021 Mar; 51(3):321-332. PubMed ID: 33324990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and Clinical Research Progress on PD-1/PD-L1-Based Immunotherapy for Metastatic Triple-Negative Breast Cancer.
    Ren Y; Song J; Li X; Luo N
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking.
    He R; Yuan X; Chen Z; Zheng Y
    Int Immunopharmacol; 2022 Dec; 113(Pt B):109444. PubMed ID: 36402069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer.
    Sivapiragasam A; Ashok Kumar P; Sokol ES; Albacker LA; Killian JK; Ramkissoon SH; Huang RSP; Severson EA; Brown CA; Danziger N; McGregor K; Ross JS
    Cancer Med; 2021 Jan; 10(1):53-61. PubMed ID: 33314633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint molecules B7-H6 and PD-L1 co-pattern the tumor inflammatory microenvironment in human breast cancer.
    Cherif B; Triki H; Charfi S; Bouzidi L; Kridis WB; Khanfir A; Chaabane K; Sellami-Boudawara T; Rebai A
    Sci Rep; 2021 Apr; 11(1):7550. PubMed ID: 33824367
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-1/PD-L1 Pathway in Breast Cancer.
    Schütz F; Stefanovic S; Mayer L; von Au A; Domschke C; Sohn C
    Oncol Res Treat; 2017; 40(5):294-297. PubMed ID: 28346916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current events in immunotherapy for upper aerodigestive tract cancer].
    Outh-Gauer S; Le Tourneau C; Broudin C; Scotte F; Roussel H; Hans S; Mandavit M; Tartour E; Badoual C
    Ann Pathol; 2017 Feb; 37(1):79-89. PubMed ID: 28111039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches.
    Song D; Powles T; Shi L; Zhang L; Ingersoll MA; Lu YJ
    J Pathol; 2019 Oct; 249(2):151-165. PubMed ID: 31102277
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PD-L1/PD-1 axis as a potent therapeutic target in breast cancer.
    Bastaki S; Irandoust M; Ahmadi A; Hojjat-Farsangi M; Ambrose P; Hallaj S; Edalati M; Ghalamfarsa G; Azizi G; Yousefi M; Chalajour H; Jadidi-Niaragh F
    Life Sci; 2020 Apr; 247():117437. PubMed ID: 32070710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-1/PD-L1 immune checkpoint blockade-based combinational treatment: Immunotherapeutic amplification strategies against colorectal cancer.
    Chen Y; Liu C; Zhu S; Liang X; Zhang Q; Luo X; Yuan L; Song L
    Int Immunopharmacol; 2021 Jul; 96():107607. PubMed ID: 33831809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-1/PD-L1 axis importance and tumor microenvironment immune cells.
    Lotfinejad P; Kazemi T; Mokhtarzadeh A; Shanehbandi D; Jadidi Niaragh F; Safaei S; Asadi M; Baradaran B
    Life Sci; 2020 Oct; 259():118297. PubMed ID: 32822718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.